Financhill
Sell
45

BIS Quote, Financials, Valuation and Earnings

Last price:
$18.72
Seasonality move :
-8.93%
Day range:
$18.46 - $18.73
52-week range:
$14.05 - $25.87
Dividend yield:
3.48%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
7.8K
Avg. volume:
9.8K
1-year change:
5.7%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIS
ProShares UltraShort Nasdaq Biotechnology
-- -- -- -- --
FXP
ProShares UltraShort FTSE China 50
-- -- -- -- --
MYY
ProShares Short MidCap400
-- -- -- -- --
PSQ
ProShares Short QQQ
-- -- -- -- --
QID
ProShares UltraShort QQQ
-- -- -- -- --
SQQQ
ProShares UltraPro Short QQQ
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIS
ProShares UltraShort Nasdaq Biotechnology
$18.72 -- -- -- $0.13 3.48% --
FXP
ProShares UltraShort FTSE China 50
$11.63 -- -- -- $0.50 8.78% --
MYY
ProShares Short MidCap400
$19.23 -- -- -- $0.16 4.84% --
PSQ
ProShares Short QQQ
$35.89 -- -- -- $0.34 6.89% --
QID
ProShares UltraShort QQQ
$28.52 -- -- -- $0.37 7.69% --
SQQQ
ProShares UltraPro Short QQQ
$23.40 -- -- -- $0.48 12.18% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIS
ProShares UltraShort Nasdaq Biotechnology
-- -2.640 -- --
FXP
ProShares UltraShort FTSE China 50
-- 0.087 -- --
MYY
ProShares Short MidCap400
-- -1.421 -- --
PSQ
ProShares Short QQQ
-- -1.191 -- --
QID
ProShares UltraShort QQQ
-- -2.389 -- --
SQQQ
ProShares UltraPro Short QQQ
-- -3.537 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIS
ProShares UltraShort Nasdaq Biotechnology
-- -- -- -- -- --
FXP
ProShares UltraShort FTSE China 50
-- -- -- -- -- --
MYY
ProShares Short MidCap400
-- -- -- -- -- --
PSQ
ProShares Short QQQ
-- -- -- -- -- --
QID
ProShares UltraShort QQQ
-- -- -- -- -- --
SQQQ
ProShares UltraPro Short QQQ
-- -- -- -- -- --

ProShares UltraShort Nasdaq Biotechnology vs. Competitors

  • Which has Higher Returns BIS or FXP?

    ProShares UltraShort FTSE China 50 has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares UltraShort FTSE China 50's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- --
    FXP
    ProShares UltraShort FTSE China 50
    -- -- --
  • What do Analysts Say About BIS or FXP?

    ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraShort FTSE China 50 has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares UltraShort FTSE China 50, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares UltraShort FTSE China 50.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    0 0 0
    FXP
    ProShares UltraShort FTSE China 50
    0 0 0
  • Is BIS or FXP More Risky?

    ProShares UltraShort Nasdaq Biotechnology has a beta of -1.451, which suggesting that the stock is 245.093% less volatile than S&P 500. In comparison ProShares UltraShort FTSE China 50 has a beta of -0.951, suggesting its less volatile than the S&P 500 by 195.107%.

  • Which is a Better Dividend Stock BIS or FXP?

    ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 3.48%. ProShares UltraShort FTSE China 50 offers a yield of 8.78% to investors and pays a quarterly dividend of $0.50 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares UltraShort FTSE China 50 pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIS or FXP?

    ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares UltraShort FTSE China 50 quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares UltraShort FTSE China 50's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares UltraShort FTSE China 50's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares UltraShort FTSE China 50. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- -- --
    FXP
    ProShares UltraShort FTSE China 50
    -- -- -- --
  • Which has Higher Returns BIS or MYY?

    ProShares Short MidCap400 has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares Short MidCap400's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- --
    MYY
    ProShares Short MidCap400
    -- -- --
  • What do Analysts Say About BIS or MYY?

    ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Short MidCap400 has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares Short MidCap400, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares Short MidCap400.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    0 0 0
    MYY
    ProShares Short MidCap400
    0 0 0
  • Is BIS or MYY More Risky?

    ProShares UltraShort Nasdaq Biotechnology has a beta of -1.451, which suggesting that the stock is 245.093% less volatile than S&P 500. In comparison ProShares Short MidCap400 has a beta of -1.113, suggesting its less volatile than the S&P 500 by 211.252%.

  • Which is a Better Dividend Stock BIS or MYY?

    ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 3.48%. ProShares Short MidCap400 offers a yield of 4.84% to investors and pays a quarterly dividend of $0.16 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Short MidCap400 pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIS or MYY?

    ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Short MidCap400 quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares Short MidCap400's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Short MidCap400's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares Short MidCap400. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- -- --
    MYY
    ProShares Short MidCap400
    -- -- -- --
  • Which has Higher Returns BIS or PSQ?

    ProShares Short QQQ has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares Short QQQ's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- --
    PSQ
    ProShares Short QQQ
    -- -- --
  • What do Analysts Say About BIS or PSQ?

    ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Short QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares Short QQQ, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares Short QQQ.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    0 0 0
    PSQ
    ProShares Short QQQ
    0 0 0
  • Is BIS or PSQ More Risky?

    ProShares UltraShort Nasdaq Biotechnology has a beta of -1.451, which suggesting that the stock is 245.093% less volatile than S&P 500. In comparison ProShares Short QQQ has a beta of -1.175, suggesting its less volatile than the S&P 500 by 217.46%.

  • Which is a Better Dividend Stock BIS or PSQ?

    ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 3.48%. ProShares Short QQQ offers a yield of 6.89% to investors and pays a quarterly dividend of $0.34 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Short QQQ pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIS or PSQ?

    ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Short QQQ quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares Short QQQ's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Short QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares Short QQQ. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- -- --
    PSQ
    ProShares Short QQQ
    -- -- -- --
  • Which has Higher Returns BIS or QID?

    ProShares UltraShort QQQ has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares UltraShort QQQ's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- --
    QID
    ProShares UltraShort QQQ
    -- -- --
  • What do Analysts Say About BIS or QID?

    ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraShort QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares UltraShort QQQ, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares UltraShort QQQ.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    0 0 0
    QID
    ProShares UltraShort QQQ
    0 0 0
  • Is BIS or QID More Risky?

    ProShares UltraShort Nasdaq Biotechnology has a beta of -1.451, which suggesting that the stock is 245.093% less volatile than S&P 500. In comparison ProShares UltraShort QQQ has a beta of -2.326, suggesting its less volatile than the S&P 500 by 332.637%.

  • Which is a Better Dividend Stock BIS or QID?

    ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 3.48%. ProShares UltraShort QQQ offers a yield of 7.69% to investors and pays a quarterly dividend of $0.37 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares UltraShort QQQ pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIS or QID?

    ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares UltraShort QQQ quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares UltraShort QQQ's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares UltraShort QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares UltraShort QQQ. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- -- --
    QID
    ProShares UltraShort QQQ
    -- -- -- --
  • Which has Higher Returns BIS or SQQQ?

    ProShares UltraPro Short QQQ has a net margin of -- compared to ProShares UltraShort Nasdaq Biotechnology's net margin of --. ProShares UltraShort Nasdaq Biotechnology's return on equity of -- beat ProShares UltraPro Short QQQ's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- --
    SQQQ
    ProShares UltraPro Short QQQ
    -- -- --
  • What do Analysts Say About BIS or SQQQ?

    ProShares UltraShort Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraPro Short QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares UltraShort Nasdaq Biotechnology has higher upside potential than ProShares UltraPro Short QQQ, analysts believe ProShares UltraShort Nasdaq Biotechnology is more attractive than ProShares UltraPro Short QQQ.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    0 0 0
    SQQQ
    ProShares UltraPro Short QQQ
    0 0 0
  • Is BIS or SQQQ More Risky?

    ProShares UltraShort Nasdaq Biotechnology has a beta of -1.451, which suggesting that the stock is 245.093% less volatile than S&P 500. In comparison ProShares UltraPro Short QQQ has a beta of -3.439, suggesting its less volatile than the S&P 500 by 443.885%.

  • Which is a Better Dividend Stock BIS or SQQQ?

    ProShares UltraShort Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 3.48%. ProShares UltraPro Short QQQ offers a yield of 12.18% to investors and pays a quarterly dividend of $0.48 per share. ProShares UltraShort Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares UltraPro Short QQQ pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIS or SQQQ?

    ProShares UltraShort Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares UltraPro Short QQQ quarterly revenues of --. ProShares UltraShort Nasdaq Biotechnology's net income of -- is lower than ProShares UltraPro Short QQQ's net income of --. Notably, ProShares UltraShort Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares UltraPro Short QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares UltraShort Nasdaq Biotechnology is -- versus -- for ProShares UltraPro Short QQQ. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIS
    ProShares UltraShort Nasdaq Biotechnology
    -- -- -- --
    SQQQ
    ProShares UltraPro Short QQQ
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 28

SharpLink Gaming [SBET] is down 16.77% over the past day.

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is down 1.73% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is down 1.31% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock